Japan-based Astellas Pharma Inc. has entered into a strategic collaboration with US-based Mass General Brigham that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.

Initial projects of mutual interest will be focused in key areas of R&D investment for Astellas, including oncology, rare disease, and cell and gene therapy. Through the alliance, Astellas and Mass General Brigham aim to accelerate innovation through collaborative research, as well as exploring and expanding new research frontiers; translate innovative research into clinical trials and actionable solutions that address serious unmet needs and aim to improve healthcare for all; and leverage scientific and clinical expertise to inform and accelerate the development of novel therapies.

Academic collaborations are a critical component of Astellas' innovation strategy. They underpin the company's ongoing commitment to enhance scientific knowledge, better understand diseases and modalities, optimise clinical trials, and ultimately, transform patient care. Located in Boston, Massachusetts, Mass General Brigham is one of the leading academic medical centers in the United States. This collaboration will leverage Mass General Brigham's clinical and research expertise, and capabilities including clinical data and human-derived cell models.